Lukas Rindlisbacher - Profile and Investment Details

Investor Profile

Lukas Rindlisbacher is a Venture Capital, Private Equity Firm based in Switzerland with a diverse investment portfolio that includes companies such as Black Diamond Therapeutics, Blueprint Medicines, TRACON Pharmaceuticals, Jounce Therapeutics, Peloton Therapeutics, Arvinas, Cullinan Oncology, Silverback Therapeutics, Sunesis PharmaceuticalsMolecularMD, MOMA Therapeutics, Scorpion Therapeutics, PMV Pharmaceuticals, Cleave Therapeutics, Vividion Therapeutics, Turning Point Therapeutics, ImaginAb, Neon Therapeutics, Telormedix, Ganymed Pharmaceuticals, Circle Pharma, EQRx, Kronos Bio, A2 Biotherapeutics, TetraLogic Pharmaceuticals, Kinnate Biopharma, Arrakis Therapeutics, Revolution Medicines, Kura Oncology, IconOVir Bio, IDEAYA Biosciences, Autolus, C4 Therapeutics, Agensys, . Over time, Lukas Rindlisbacher has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Lukas Rindlisbacher is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Women Founded, Life Science, Information Technology (IT), Biotechnology, Research, Travel, Medical, Therapeutics, Pharmaceuticals may find it worthwhile to explore potential connections with Lukas Rindlisbacher, as their portfolio suggests a familiarity and interest in this area.

Understanding Lukas Rindlisbacher’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.